Money Maker
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I had the same reaction... blowout numbers... added to my position on the recent pullback... feeling very confident that we move significantly higher over the short-term... anything under $4.00 is a gift IMO...
The PPS has no business sitting sub $3.00... just sayin'...
$GRWG
Been frying bigger fish... $CVSI has been dead money for a while... sitting on my share playing with free money...
On another note... how about listing positive developments... most of what you are stating is a matter of opinion with a few facts sprinkled in to confirm your negativity... bottom line... $CVSI is best in class... the numbers speak for themselves...
One of the most ridiculous statements I've seen here... this is a joke right?...
My argument has always been there are other places more money could have been made, and that is true.
Stellar earning report... THEY ARE PROFITABLE!... should be $6-$7 min based on their numbers...
Adjusted EBITDA of $615,509 for Q1 2019 compared to adjusted EBITDA of $(366,945) for Q1 2018.
Net income of $229,421 for Q1 2019 compared to a net loss of $(953,430) for Q1 2018.
Revenue of $13.1 million up $8.7 million or 199% over Q1 2018 revenues of $4.4 million .
Same store sales were up 42% for Q1 2019 compared to Q1 2018.
Acquired stores in Denver, CO , Palm Springs, CA and Reno, NV , and opened Tulsa, OK and Brewer, ME locations in 2019.
Gross profit margin percentage was 28.2% for Q1 2019 compared to 27.1% for Q1 2018.
Store operating costs, as a percentage of revenue, have declined 26% from 20.4% for Q1 2018 to 15% for Q1 2019.
Corporate overhead declined 107%, from 21.8% of revenues for Q1 2018 to 10.5% of revenue for Q1 2019.
The Company had $6.6 million in cash and cash equivalents at March 31, 2019 .
As of March 31, 2019 , the Company had working capital of $17.4 million compared to working capital of $21.6 million at December 31, 2018 .
https://finance.yahoo.com/news/growgeneration-reports-record-q1-2019-130000460.html
Unbelievable!... I can't believe you're still here downplaying $CVSI... I also see that you're still wrong... LMAO!...
$CVSI... the 800 pound gorilla!
Bounce here... getting ready to trade higher IMO... $5.50 resistance... also at 50% fibs...
$CVSI
Almost pulled the trigger this morning on a small block... past few session could be simply an oversold trading bounce... Don't like that gap back in December that was never filled... would love a sharp selloff that fills that... regardless... the company is as solid as they come...
I'm patiently waiting for the right opportunity... I want a piece of this action...
$SOLCF
Looks like they want to take this lower IMO...
$EDXC
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. Recently, the company announced a new agreement with the Colorado Hemp Project to develop and cultivate boutique genetics and new strains of hemp which will provide the key ingredient in proprietary CBD formulations. The mission statement of the Colorado Hemp Project is: an organic hemp farm consulting agency that works with local farmers and municipalities across the globe to bring hemp cultivars and resources to the communities that need it the most, with the sole intention of healing the planet by accelerating the establishment of local, sustainable hemp farms and companies everywhere. GB Sciences believes that hemp will provide an important palette upon which important compounds can be created, and believes that, ultimately, hemp will provide a relatively inexpensive source of important and beneficial cannabinoids. GB Sciences will breed CBD into the genetics of the hemp plants and then analyze and optimize results.
Clinical Cannabis: How GB Sciences is Redefining the Industry Through Research
Las Vegas’ GB Sciences is using controlled cultivation, specific product formulations and dedicated research to redefine how the industry thinks of medical cannabis.
Dr. Andrea Small-Howard, co-founder and chief science officer of Nevada-based GB Sciences, wants to redefine what is understood and expected of today’s medical cannabis industry.
She doesn’t consider GB Sciences to be a “medical cannabis” producer in any traditional sense. And while the 28,000-square-foot pharmaceutical-grade facility in Las Vegas serves the state’s adult-use market, that recreational side of the business is even less a part of the company’s branded identity.
Instead, Small-Howard prefers GB Sciences be referred to as a “clinical cannabis” company, because “we are not content to simply produce bulk products," she says, adding, "We are going the extra mile to get evidence behind the products that we are going to provide."
This distinction between medical and clinical cannabis is an interesting concept for the entire industry: Without the institutional knowledge that supports the medicinal claims of current pharmaceutical substances or compounds, can the medical cannabis industry confidently say that it is offering medicine?
That isn’t to say that patients don’t receive health benefits from the various compounds and formulations found in cannabis varieties, as the entire GB Sciences team is quick to point out. Rather, little to no evidence exists to confirm that the ways cannabis is being used to treat certain conditions are the most effective ways to use it. Small-Howard and her team hope to establish—and share—that knowledge.
Business launch date: Received provisional medical cultivation license in 2014
Location: Las Vegas, Nev.; Baton Rouge, La.
Cultivation/canopy size: 10,000 square feet of canopy
Number of employees: 50-75
Products offered: Flower, pre-rolls, rosin press and ethanol extracts, vape pens, tinctures and new medical products in development
Fast Take with Andrea Small-Howard, Co-Founder and CSO, GB Sciences
Biggest challenge in launching or maintaining a cultivation business: “Maintaining the fidelity of our genetic lines and the standardization of our raw cannabis materials. We are also always making sure that we’re staying up to date with the ever-changing state regulations.”
Something people don’t realize about running a cannabis operation: “It’s a fairly complicated value chain. Maintaining a vision of the entire chain with a patient-centric focus is crucial for production planning.”
Some lessons learned: “Make sure you really understand the motivations of your partners before you get involved. Do your due diligence before you take that leap.”
What keeps you awake at night: “My personal mission is to take cannabis-based therapies to the U.S. FDA, so I wonder how things are going to change … when the federal status of cannabis [changes].”
What helps you sleep at night: “Something with a large amount of CBN (laughs). I’m pretty happy with the current partners we are working with. I’m happy to have a group of people who are all motivated and working in the same direction.”
Advice for other cultivators: “Implementing a Quality Control System can make all the difference in managing the details that produce standardized products—and keep cultivation and production cranking!"
Clinical Growth: Tissue Culture Cloning
According to GB Sciences, the most effective way to avoid genetic mutations from one clone to the next—which would cause the variations in product formulations that the company is trying avoid—is not to use clones, but instead opt for tissue culture.
Tissue culture, more precisely called tissue culture micro-propagation, is the cloning practice by which a genetically identical plant is created by scraping only a few newly formed cells from the plant tissue of a mother plant. Those cells then multiply in sterile replication trays until they grow shoots and then roots, at which point the plants receive standard clone treatment. Essentially, “it’s an aseptic technique to clean … a strain,” says Dominick P. Monaco, director of product quality and development at GB Sciences. “Utilizing that technique, you can minimize genetic [mutations] from your original cultivar that you originally brought in the building.” And when you bring that process in-house as GB Sciences did, “You can maximize your production space,” he says.
In a room no bigger than 300 square feet, Monaco and his cultivation team can feed a veg room with enough steady supply to keep four 50-light flower rooms in perpetual harvest. The only drawback in Monaco’s opinion is that it takes longer for those micro-propagated tissues to develop into mature enough plants to be transferred into a veg room—about four to six extra weeks, he says. However, he adds that, “You'll only ever incur that when you start your operation, as long as you stick to a schedule.”
Ensuring all the facility’s operations are on schedule is essential for the same reason that tissue culture is better suited for GB Sciences than clones: Any deviation from the plan could lead to a change in the phytochemistry of a given cultivar and throw off the delicate balance of the company's formulas. How can you know that your clinical product is working correctly if its components keep changing?
Monaco works hard to maintain GB Sciences' quality management system (QMS). The company adheres to mandatory state cannabis regulations and is phasing in optional International Standardization Organization (ISO) and International Conference on Harmonization (ICH) standards, as a way to ensure each task gets tackled the same way no matter whose assignment it is.
“It’s a very overarching system to point everybody in the same direction, make sure that there's clear, concise communication, and that there's documentation for everything that's going on,” Monaco says of the company’s QMS. “If there's any deviation from the protocol … [it] is also documented and is reviewed to see why it happened, how to prevent it in the future, and how to implement that [change] going forward.”
Training staff to adhere to those standards and hiring someone like a quality manager (Monaco’s first job at GB Sciences) to make sure the day-to-day activities are correctly done are also crucial. “The key about a good quality manager is that they need to be able to spot when deviations happen but also at the same time, not interrupt production,” he says. Spotting deviations without interrupting production requires a mix of daily plant inspection and data analysis.
The dozen sensors installed in each plant room track everything from ambient temperatures, humidity, VPD, and CO2 concentrations at both ground- and ceiling-level. By measuring CO2 levels near the ceiling (at the point where the gas enters the room) and near the floor (where it should be pooling), Monaco and his team can see how much CO2 the plants are consuming. High gas levels at the floor and ceiling “means that our vapor pressure deficit is probably off and [the plants] are probably not consuming that CO2,” Monaco says. High levels at the top and low levels at the bottom means plants are consuming the CO2 appropriately, while low levels of CO2 at the ceiling indicates either a CO2 line is plugged or a defective sensor.
Rockwool cubes are the medium of choice for any sterile environment, according to Monaco. As an inert medium, rockwool is also easy to monitor for pH, water content and nutrient levels, all of which must be in a precise range if the company wants to maintain standardized phytochemical output from its cultivars.
In addition to adopting standard cleanroom protocols and rockwool, GB Sciences installed 16 UVC air sterilization units inside the building to disinfect every air exchange that happens in any grow room. Each unit houses four UVC bulbs that sterilize all the air entering and exiting any grow room. The facility’s water (which already undergoes a reverse osmosis process) is also subject to UVC light treatment to eliminate any potential bacterial or fungal presence.
“GB is spending the time and the resources to do the science right and to make sure that we're gonna be ahead of the game when the national regulatory environment opens up for us,” Monaco says.
In Case You Missed It: GB Sciences Approved For Full Operations In Main LSU AgCenter Production Facility
With over five times the production capacity, main facility will allow for a perpetual harvest cycle, ensuring a continuous supply of therapeutic cannabis for patients throughout Louisiana.
GB Sciences (OTCQB:GBLX), a partner in GB Sciences Louisiana, LLC, announces that all cultivation operations at LSU Agricultural Center are now open.
This will allow a continuous harvest for patients by increasing the production capacity 500%.
GB Sciences Louisiana's two previous successful harvests passed state testing requirements. These formulations will be submitted to Louisiana's state regulator for continuous testing and ultimately distributed to the nine licensed pharmacies around the state.
----------------------
LAS VEGAS, March 26, 2019 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) today announced that The LSU Agricultural Center (AgCenter) received confirmation from the Louisiana Department of Agriculture and Forestry (LDAF) that GB Sciences Louisiana is deemed suitable for full-scale operations.
Now that the favorable suitability determination has been released by LDAF, GB Sciences Louisiana will commence full operations within the main production facility. This facility is equipped with modular clean room technology for use in the production of plants and formulation of final products. The main production facility has more than five times the production capacity of the small exterior facility that GB Sciences Louisiana has been operating. This increase in space will allow for a perpetual harvest cycle, ensuring a continuous supply of product for patients with qualifying disease states.
Two previous successful harvests in the small exterior facility will allow GB Sciences Louisiana to soon begin the creation of final formulations. These formulations will be submitted to LDAF for final testing and ultimately distributed to the nine licensed pharmacies around the state.
"This is a great day for patients," said GB Sciences Louisiana President John Davis. "Full-scale operations means a consistent and continuous supply of medical cannabis. We are thrilled to move into our main facilities."
The LSU AgCenter conducted a thorough competitive public bid process in 2017, and examined and selected GB Sciences Louisiana as its public-private partner. GB Sciences was approved by LDAF in August 2018 to grow, extract, and formulate in a small exterior facility on the site premises while construction on their main production facility was underway. GB Sciences Louisiana completed the construction of their main production facility in October 2018. Since that date, the facility has received the "certificate of occupancy" from LDAF and the Standard Operating Procedures have been approved.
"The LSU AgCenter and GB Sciences Louisiana have worked diligently on this initiative since GB's selection in September 2017. We are very happy to have this milestone completed and we look forward to getting this much-needed product out to the patients of Louisiana," said William B. Richardson, LSU Vice President for Agriculture.
Holding .15... solid support... will go higher when product hits the shelves... IMO we see nice catalysts hit over the next few months that will drive the price up to a more reasonable level...
$GBLX...
XXII = Beast Mode... we break through $2.30 - $2.40 resistance, it's off to the races IMO...
$XXII
Positive cash flow is not a "Problem"... no one is denying your statement... $EDXC simply needs to take one step back to move two steps forward... that's all...
Problem is the company EDXC has a positive cash flow and the Phyto Bites will help keep the positive flow going up and to the right.
Test of .40 coming... IMO this could dip into the low .30's again, possibly the .20's... trade on...
$EDXC
It's a beautiful thing... lol!
On another note... solid day put in... looking more of the same tomorrow...
I have that person on ignore... he sounds like a used car salesman... LMAO!!... the agenda is quite clear...
On another note... the selling pressure looks like it is over... looking forward to a nice pop here...
$GBLX
Still holding my original shares... I actually added to my position recently... absolutely agree with you... up listing would be a nice catalyst... this is the type of stock that has the potential to pop 50% - 100% in a blink of an eye... IMO lots of upside potential... we simply need more coverage... up listing would do that...
$VRNDF
In due time... beautiful consolidation over the past month... IMO we leg up over the next few weeks... next stop $3.00... all IMO...
Damn I love this company!...
$CNXXF
Not too many eyes on $CNPOF right now... key words... right now... the company is moving and shaking and making things happen... solid revenue, cash and Canopy Growth owns 27.3%... Crazy we are not trading above $5.00... significantly undervalued at this level IMO... Added to my position last week...
Long $CNPOF
When I bought this company I bought the CEO... Very impressed with their progress and vision... I'm particularly interested in NanoSphere... IMO delivery of cannabis through phospholipid nanoparticle technology is the future of medicinal cannabis dosing. Their relationship with Canopy is also big.
Most see this as dead money... I see this as a buying opportunity... One negative is the amount of shares insider own... It's a known institutional deterrent...IMO this is one of the reasons why the share price is sitting where it is...
Only a matter of time IMO...
$VRNDF
More coverage initiated... looks like we are getting ready to rock and roll...
Principal Financial Group Inc. Invests $40,000 in 22nd Century Group Inc (XXII)
https://www.fidaily.com/2019/04/28/principal-financial-group-inc-invests-40000-in-22nd-century-group-inc-xxii.html
11,123 Shares in 22nd Century Group Inc (XXII) Purchased by Mercer Global Advisors Inc. ADV
https://www.fidaily.com/2019/04/27/11123-shares-in-22nd-century-group-inc-xxii-purchased-by-mercer-global-advisors-inc-adv.html
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Geode Capital Management LLC lifted its holdings in shares of 22nd Century Group by 13.5% during the fourth quarter. Geode Capital Management LLC now owns 1,166,476 shares of the biotechnology company’s stock worth $2,904,000 after buying an additional 139,131 shares in the last quarter. Advisory Services Network LLC bought a new position in shares of 22nd Century Group in the fourth quarter worth $142,000. Amalgamated Bank bought a new position in shares of 22nd Century Group in the fourth quarter worth $44,000. HRT Financial LLC bought a new position in shares of 22nd Century Group in the fourth quarter worth $33,000. Finally, Cetera Advisors LLC increased its position in shares of 22nd Century Group by 16.9% in the fourth quarter. Cetera Advisors LLC now owns 27,615 shares of the biotechnology company’s stock worth $68,000 after purchasing an additional 4,000 shares during the period.
$XXII
$GRWG... another hidden gem...
Bought in a month back... patiently waiting for this to break out of this consolidation area and head higher... much higher... only a matter of time IMO before price catches up with earnings growth and valuation.
$GRWG
My original post... What are you talking about? MACD and MA dude... at no point is A/D brought up...
Unfortunately the $EDXC party may be over short-term IMO. Weekly and daily MACD is still way overbought... looking for a trade down to the 50day MA... .20's are not out of the question ... IMO we see a month of consolidation before resuming the uptrend. Zero to do with the health of the company, just my technical opinion... either way... I'm ready...
Play it as you see it...
$EDXC
$NACNF... a hidden gem... only a matter of time until this makes a major move higher IMO... the fundamentals are outstanding... the price will eventually catch up... need some coverage and more PR... Speaking of PR, I hear the CEO is not too keen on news... he believes the company should be the driving factor, not P&D PR... I like that...
Below is a link to a video (though dated) of an interview with the CEO... very nice piece...
Earnings eve... anyone else feel like its Christmas Eve?... Lets just hope we don't get coal... Ready for $ALEAF to break out of this downtrend...
Long $ALEAF
Please don't put words in my mouth... I rarely use A/D to support my analysis... There are a plethora of other technical indicators that support my opinion... A/D ain't one of them... A/D has been parabolic and IMO has peaked... it is meaningless to me at this point...
I believe the weekly chart speaks volumes as to the direction we are headed short-term... The MACD tells the real story... over extended and topped out... not to mention RSI is still in the low to mid 70's and has been all year... a sell down to 50 RSI would set us up nicely for the next leg... all IMO...
Disclaimer: I am long $EDXC and have been for many years... I continue to hold approx 40% of my original position... I sold 60% into strength... low .40's fist 30% sold... at .70 additional 30% sold... Trust me... I want to see this at $5.00 too... just need some major consolidation before this heads higher... again... all in my opinion...
$EDXC
Unfortunately it does... good luck...
$EDXC
Thank you my friend... I haven't been paying much attention to the details here... just holding my core position and waiting...
Unfortunately the $EDXC party may be over short-term IMO. Weekly and daily MACD is still way overbought... looking for a trade down to the 50day MA... .20's are not out of the question ... IMO we see a month of consolidation before resuming the uptrend. Zero to do with the health of the company, just my technical opinion... either way... I'm ready...
Play it as you see it...
$EDXC
Also... Quadrupedal test of .15... this chart is confirming a bottom when looking at a longer time period... .30 - .40 range coming IMO... time to load... downside risk is extremely minimal... again all IMO...
Theses are the FACTS!
The share price has little to do with management or the company... It's impossible to execute when what you are doing is against the law... now that LA is on board, revenue will start coming in. It also explains their debt position, dilution and weak earnings. Considering their anemic market cap (which always is overlooked here) and their peers, this should be trading 2-3x's higher than current share price.
Bottom line... $GBLX is worth considerable more that .16 a share. Future earnings look very promising. it's only a matter of time until valuation catches up to it's peers...
Looks like this has found solid support @ .15... Historically we have significantly bounced off of this level...
I've attached a screenshot for the doubters...
Long $GBLX
Old news... many things have changed since January... How about the plethora of frivolous class actions... wild share price fluctuations earlier this year, etc... This is the stock market... dynamics change daily... next time, how about sharing some of my positive posts... man you went back deep into my archives to find this... lol!
Gap down...
$YOLO... nice!
Fell quicker than anticipated... low .40s coming IMO... testing some of these support levels is absolutely necessary in order to move forward... need a more significant pullback, these short-term gains are unrealistic...
Licking my chops for .40's...
$EDXC
A pullback to the low .50 is not out of the question... Healthy pullback would take us into the low to mid .40's... All IMO...
$EDXC
Some of us have been here sub .10... simple profit taking...
On another note... these flash crashes offer nice trading opportunities...
$EDXC
Nice post!... spot on...
Still cant believe the low volatility... I agree... looks like this is setting up for something big...
$GRWG